Latest filing published 24 Oct 2025 for KALA BIO, Inc., €33k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Romulus K. Brazzell, listed as senior executive, appears in our data through filings on KALA BIO, Inc. shares, published by SEC (Form 4). In total, 15 filings cover trades dated from 28 June 2021 to 22 October 2025.
The open-market record consists of 10 sales worth €141k, with no purchase. The rest of the record consists of 5 share grants. Since January 2025: no purchases and 3 sales on the market.
Most recently, on 24 October 2025, the filings show an open-market sale worth €33k in KALA BIO, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations